Key result
Fast-track anesthesia with remifentanil and dexmedetomidine is linked to shorter ventilation and ICU stays.
Why the study?
The safety and efficacy of remifentanil combined with dexmedetomidine in fast-track cardiac anesthesia for transthoracic device closure of ASD in pediatric patients needed investigation.
Does fast-track cardiac anesthesia with remifentanil and dexmedetomidine reduce mechanical ventilation duration and ICU stay in pediatric patients undergoing transthoracic device closure of atrial septal defect?
Cohort (n=61)
Does fast-track cardiac anesthesia with remifentanil and dexmedetomidine reduce mechanical ventilation duration and ICU stay in pediatric patients undergoing transthoracic device closure of atrial septal defect?
p-value: p=<.05
Remifentanil combined with dexmedetomidine for fast-track cardiac anesthesia safely reduces mechanical ventilation duration and ICU stay in pediatric patients undergoing ASD closure.
Should not yet change anesthesia protocols; leaves open confirmation of benefit in randomized cardiac surgery trials.
BACKGROUND: To investigate the safety and efficacy of remifentanil combined with dexmedetomidine in fast-track cardiac anesthesia (FTCA) for transthoracic device closure of atrial septal defect (ASD) in pediatric patients. METHODS: A retrospective analysis was performed on 61 cases of children undergoing ASD closure through a small thoracic incision from January 2018 to January 2020. According to whether FTCA was administered, they were divided into group F (fast-track anesthesia, n = 31) and group R (routine anesthesia, n = 30). RESULTS: There was no significant difference in general preoperative data, perioperative hemodynamics, or postoperative pain scores between the 2 groups (P > .05). The postoperative sedation score of group F was higher than that of group R 1 and 4 hours after extubation. Meanwhile, duration of mechanical ventilation and length of postoperative intensive care unit (ICU) stay of group F were significantly shorter than those of group R (P < .05). No serious anesthesia-related complications occurred. CONCLUSION: Remifentanil combined with dexmedetomidine in FTCA for transthoracic device closure of ASD in pediatric patients is safe and effective, is worthy of clinical promotion, and can benefit more children.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2021) conducted a cohort in Atrial septal defect (ASD) (n=61). Remifentanil combined with dexmedetomidine in fast-track cardiac anesthesia (FTCA) vs. Routine anesthesia was evaluated on Duration of mechanical ventilation and length of postoperative intensive care unit (ICU) stay (p=<.05). Fast-track cardiac anesthesia with remifentanil and dexmedetomidine significantly shortened the duration of mechanical ventilation and postoperative ICU stay compared to routine anesthesia (P < .05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: